Does VATS lobectomy improve lung cancer survival?

VATS vs open lobectomy: survival advantage without worse disease control

An individual-patient-data meta-analysis of randomized lung-cancer trials found that video-assisted thoracoscopic surgery (VATS) lobectomy improves overall survival compared with open surgical lobectomy.

The key takeaway is that the survival benefit does not appear to come at the expense of cancer control. Across the pooled trials, VATS was associated with better overall outcomes while disease-free survival was not compromised.

This matters because lobectomy is a standard operation for resectable lung cancer, but the broader question for clinicians and patients has been whether the minimally invasive approach meaningfully changes long-term results. Surgical technique can influence recovery, complication rates, and the timing/feasibility of any needed follow-up therapy, all of which can ultimately affect survival.

What the evidence supports

• Overall survival: improved with VATS compared with open surgery.
• Disease-free survival: no evidence of a trade-off; it was not worsened.

While the meta-analysis synthesizes multiple randomized studies—strengthening the evidence base beyond any single trial—it still reflects what happened under the trial protocols and surgical practices used in those studies. Real-world results can vary based on patient characteristics and local surgical expertise.

For patients deciding between approaches, the finding offers more reassurance that choosing VATS, when feasible, may provide a long-term survival advantage while maintaining disease-free outcomes. For health systems, it strengthens the clinical rationale for supporting VATS capability and training, since long-term cancer outcomes are not just presumed based on “less invasive” theory but supported by trial-level pooled data.